When is patient transfer indicated for the treatment of Smith-Lemli-Opitz syndrome (SLOS)?

Updated: Jan 27, 2021
  • Author: Robert D Steiner, MD; Chief Editor: Luis O Rohena, MD, MS, FAAP, FACMG  more...
  • Print

In the newly diagnosed fetus, newborn, or young infant, transfer to a tertiary care academic facility where a medical geneticist or metabolic-disease specialist is immediately available and pediatric general surgeons and appropriate pediatric surgical subspecialists are available may be required. In some cases, the infant may be too ill and unstable to transport.

Transfer or intermittent visits to a facility where active clinical research in Smith-Lemli-Opitz syndrome is ongoing may be considered in any age group.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!